SFN and neoplasm: Conversely, monocyte pre-treatment with anti-αMβ2 monoclonal antibody only inhibited adherence by 22.5 ± 2.6% to untreated A375 cells, and by 80 ± 0.5% to sFn pre-treated tumor cells (P < 0.05 compared to untreated A375 cells).